Kopran Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company is focused on internal growth through CAPEX investments (Panoli plant, vial filling lines) funded approximately between Rs. 80-100 crores over the next 2-3 years. - They plan gradual backward integration and forward integration to remain competitive, without indicating external fundraising. - Management discusses growth ambitions and operational expansions but did not reference raising capital via debt or equity during this call. - Overall, the focus appears on organic growth and internal resource utilization rather than new fundraising.

- The major ongoing CAPEX is the Panoli plant, costing between ₹50 to ₹60 crores, nearing completion. - Plans to add a vial filling line for Penems, with an estimated investment of around ₹30 crores or more; decision on one or two lines is pending. - Continuous CAPEX will focus on plant automation and capacity enhancement. - Over the next 3 years, total CAPEX is expected to exceed ₹100 crores. - The vial filling line aims to insulate the company from price volatility and increase formulation margins. - No plans currently to sell KSMs; KSM production will be for in-house consumption to reduce China dependency. - USFDA approval for new Panoli facility expected to take around 3 years after validation and filing processes. - Overall, strategic investments focus on backward integration, capacity expansion, and product value addition.

- Company targets 18-20% revenue growth for the current year (FY '25). - Expect significant growth from the Panoli plant starting FY '26, with validation batches beginning soon. - Panoli plant projected to contribute Rs. 200-300 crores in revenue over 2-3 years. - API segment growth expected around 30-35% over next two years, driven by Panoli. - Formulations forecasted to grow at a steady 10-15% annually. - Shift focus from anti-infectives to chronic therapies (cardiology, diabetes, CNS) to drive growth. - Long-term revenue target of Rs. 1,200-1,300 crores in 4-5 years. - Integration of backward (KSMs) and forward (formulations) operations to improve competitiveness and margins. - Margins expected to improve gradually, targeting 20% EBITDA margin in 3-4 years.

- Kopran Limited aims to double its revenue to around INR 1,200-1,300 crores within 4-5 years (by FY '27-28). - API segment growth is projected at about 18% for FY '25, with a spike to 30-35% growth in the subsequent two years due to contributions from the new Panoli plant. - Formulations are expected to grow at 10-15% annually. - EBITDA margin is targeted to improve from around 13% currently to approximately 20% over the next 3-4 years. - The Panoli plant is expected to contribute meaningfully to revenues starting FY '26, potentially generating INR 200-300 crores over 2-3 years. - Profit growth aligns with revenue gains, aiming for consistent EBITDA improvement, supported by integration, backward integration on KSMs, and forward integration via vial filling lines. - EPS and operating profits are expected to approximately double in line with revenue and margin improvements over the medium term.

- Kopran has secured commercial orders for Atenolol in the U.S. market. - Teva, a leading generic pharmaceutical company, is transitioning its Atenolol supply to Kopran. - Teva has already placed some orders and completed validation batches with Kopran's Atenolol. - Full business transition from Teva to Kopran is expected gradually over the next 6 months to 1 year. - The anticipated order volume for Atenolol is approximately 25 to 30 tons. - This volume represents around 12% of Kopran's manufacturing capacity. - No specific figures were provided on other current or pending orders during the call.